1-5 of 5
Roxanne C Jewell, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Suzanne Trudel, MD FRCP(C), Nikoletta Lendvai, MD PhD, Rakesh Popat, MD PhD, Peter M. Voorhees, MD, Brandi Reeves, MD, Edward N. Libby, III, MD, Paul G Richardson, MD, Larry Anderson, MD PhD, Heather Sutherland, MD, Kwee Yong, PhD, Axel Hoos, MD PhD, Michele Gorczyca, MS, Soumi Lahiri, PhD, Zangdong He, PhD, Roxanne C Jewell, PhD, Joanna B. Opalinska, MD PhD, Adam D. Cohen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 741.
https://doi.org/10.1182/blood.V130.Suppl_1.741.741
Published: 2017
Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc
Journal: Blood
Blood (2012) 120 (21): 1632.
https://doi.org/10.1182/blood.V120.21.1632.1632
Published: 2012
Journal Articles

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

William G. Wierda, MD, PhD, Roxanne C. Jewell, PhD, Thomas J. Kipps, M.D., Ph.D, Jan Dürig, MD, Laimonas Griskevicius, Stephan Stilgenbauer, MD, Lukas Smolej, M.D., Ph.D., Georg Hess, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MD, Lei Fang, Michele M. Gorczyca, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Steen Lisby
Journal: Blood
Blood (2011) 118 (21): 1793.
https://doi.org/10.1182/blood.V118.21.1793.1793
Published: 2011
Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC
Journal: Blood
Blood (2010) 116 (21): 4916.
https://doi.org/10.1182/blood.V116.21.4916.4916
Published: 2010